Canada · Delayed Price · Currency is CAD Eupraxia Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
EoE is a rapidly growing market with significant unmet need, and the therapy’s once-yearly, physician-administered dosing offers strong compliance and commercial advantages. Detailed interim phase II-B data in December will address efficacy, durability, and safety, supporting expansion into additional indications.
-
The conference highlighted a novel drug delivery platform for EoE, showing rapid and sustained symptom relief, strong histological improvements, and a favorable safety profile. The upcoming phase II-B trial is expected to confirm these benefits, with significant commercial and pipeline expansion potential.
-
A novel, long-acting injectable therapy for EoE shows strong efficacy and safety, with up to 80% clinical remission at six months and sustained benefits for a year. Expansion into related GI conditions and a robust financial runway support continued development and upcoming pivotal trials.
-
Fresh clinical data show rapid, durable remission in EoE with a novel, locally delivered steroid, supported by strong safety and histology results. Well-funded through 2028, the company is expanding into benign esophageal strictures and fibrostenotic Crohn’s, targeting large, underserved GI markets.